The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33822002/
Lymphoma survivors have a significantly higher risk of developing second primary lymphoma than the general population; however, bidirectional risks of developing B- and T-cell lymphomas (BCL; TCL) specifically are less...
-
Naveed Saleh, MD, MS – Skipta Team4yrWhat are the clinical implications of these findings?
-
Naveed Saleh, MD, MS – Skipta Team4yrThanks, Dr. Fesler. Would the authors' findings influence your clinical approach in any way?
Show More Comments
Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33792219/
B-cell non-Hodgkin's lymphoma (B-NHL) encompasses multiple clinically and phenotypically distinct subtypes of malignancy with unique molecular etiologies. Common subtypes of B-NHL such as diffuse large B-cell lymphoma (DLBCL) have been...
-
DLBCL Connect4yrWhat are the specific strengths and weaknesses of this study? What future research should be done on the topic?
-
Naveed Saleh, MD, MS – Skipta Team4yrWhat are the specific strengths and limitations of this study? How about future lines of research?
Show More Comments
TITLE: Clinical application of liquid biopsy in non-Hodgkin lymphoma
SUMMARY: In the case of DLBCL or any other (less) common NHL subtype, tissue diagnosis is the gold standard. Tissue samples, however, are harvested by surgical resection or lymph node puncture, which both carry risks inherent to invasive procedures. Moreover, tissue samples are...
Clinical Application of Liquid Biopsy in Non-Hodgkin Lymphoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33816315/
Non-Hodgkin lymphoma (NHL) is a common type of hematological malignant tumor, composed of multiple subtypes that originate from B lymphocytes, T lymphocytes, and natural killer cells. A diagnosis of NHL...
-
DLBCL Connect4yrHow far off is the development of prognostic models based on cfDNA/ctDNA for NHL? In your opinion, what research still needs to be done?
-
Mark Fesler4yrOnly used in context of 10 color flow for CLL and in research setting in MCL. Few commercial platforms. Would speculate that this in conjunction with pet will improve Show More
WVU Cancer Institute Cellular Therapy Program doubles CAR-T offerings with two new treatments | WVU Medicine
MORGANTOWN, W.Va. - The WVU Cancer Institute Osborn Hematopoietic Malignancy and Cellular Therapy Program is offering two new forms of chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of...
-
DLBCL Connect4yrThis development is notable because it provides increased access to rural populations in West Virginia. Could this be a developing trend to combat health disparities?
-
Naveed Saleh, MD, MS – Skipta Team4yrAn interesting aspect here is that increased healthcare access is provided in a rural community. Perhaps a trend towards combating healthcare disparities?
Show More Comments
Impact of Hypoalbuminemia on the Prognosis of Relapsed/Refractory B‐Cell Lymphoma Treated with Axicabtagene Ciloleucel
Source : https://onlinelibrary.wiley.com/doi/abs/10.1111/ejh.13609
Mohamed A. Kharfan‐Dabaja Corresponding Author Division of Hematology‐Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USA Corresponding Author: Mohamed A.
-
Mark Fesler4yrMost surprising finding might be the two patients without a serum albumin prior to car T. That aside, there is a difficult to explain disconnect between ORR and PFS/OS Show More